Document Detail

Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure).
MedLine Citation:
PMID:  20883926     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The purpose of this study was to determine whether coenzyme Q₁₀ is an independent predictor of prognosis in heart failure.
BACKGROUND: Blood and tissue concentrations of the essential cofactor coenzyme Q₁₀ are decreased by statins, and this could be harmful in patients with heart failure.
METHODS: We measured serum coenzyme Q₁₀ in 1,191 patients with ischemic systolic heart failure enrolled in CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) and related this to clinical outcomes.
RESULTS: Patients with lower coenzyme Q₁₀ concentrations were older and had more advanced heart failure. Mortality was significantly higher among patients in the lowest compared to the highest coenzyme Q₁₀ tertile in a univariate analysis (hazard ratio: 1.50, 95% confidence interval: 1.04 to 2.6, p = 0.03) but not in a multivariable analysis. Coenzyme Q₁₀ was not an independent predictor of any other clinical outcome. Rosuvastatin reduced coenzyme Q₁₀ but there was no interaction between coenzyme Q₁₀ and the effect of rosuvastatin.
CONCLUSIONS: Coenzyme Q₁₀ is not an independent prognostic variable in heart failure. Rosuvastatin reduced coenzyme Q₁₀, but even in patients with a low baseline coenzyme Q₁₀, rosuvastatin treatment was not associated with a significantly worse outcome. (Controlled Rosuvastatin Multinational Study in Heart Failure [CORONA]; NCT00206310).
John J V McMurray; Peter Dunselman; Hans Wedel; John G F Cleland; Magnus Lindberg; Ake Hjalmarson; John Kjekshus; Finn Waagstein; Eduard Apetrei; Vivencio Barrios; Michael Böhm; Gabriel Kamenský; Michel Komajda; Vyacheslav Mareev; John Wikstrand;
Related Documents :
25189216 - The challenges of success: maintaining access to high quality pci in the face of declin...
20024636 - Biomarkers in heart failure--better than history or echocardiography?
16740226 - Is oocyte morphology prognostic of embryo developmental potential after icsi?
6837606 - Cardiac failure in addison's disease.
18381186 - Predischarge qrs score and risk for heart failure after first st-elevation myocardial i...
11967826 - Angiotensin ii binding and extracellular matrix remodelling in a rat model of myocardia...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  56     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-04     Completed Date:  2010-10-22     Revised Date:  2011-05-16    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1196-204     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, United Kingdom.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Biological Markers / blood
Fluorobenzenes / adverse effects,  therapeutic use*
Follow-Up Studies
Heart Failure / blood*,  diagnosis,  drug therapy*
Hospitalization / trends
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use*
Middle Aged
Prospective Studies
Pyrimidines / adverse effects,  therapeutic use*
Sulfonamides / adverse effects,  therapeutic use*
Treatment Outcome
Ubiquinone / analogs & derivatives*,  antagonists & inhibitors,  blood
Reg. No./Substance:
0/Biological Markers; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Sulfonamides; 1339-63-5/Ubiquinone; 287714-41-4/rosuvastatin; 303-98-0/coenzyme Q10
Comment In:
J Am Coll Cardiol. 2011 Apr 5;57(14):1569; author reply 1569   [PMID:  21453843 ]
J Am Coll Cardiol. 2010 Oct 5;56(15):1205-6   [PMID:  20883927 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary ...
Next Document:  Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.